

Ali J Olyaei

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3176664/publications.pdf>

Version: 2024-02-01

57
papers

2,936
citations

257429

24
h-index

223791

46
g-index

58
all docs

58
docs citations

58
times ranked

3377
citing authors

#	ARTICLE	IF	CITATIONS
1	The Clinical and Economic Benefit of CMV Matching in Kidney Transplant: A Decision Analysis. <i>Transplantation</i> , 2022, 106, 1227-1232.	1.0	7
2	The Principles of Drug Dosing in Peritoneal Dialysis. , 2021, , 349-374.		1
3	Optimal Timing of Administration of Direct-acting Antivirals for Patients With Hepatitis C-associated Hepatocellular Carcinoma Undergoing Liver Transplantation. <i>Annals of Surgery</i> , 2021, 274, 613-620.	4.2	3
4	Expert Consensus Statement from the American Society of Echocardiography on Hypersensitivity Reactions to Ultrasound Enhancing Agents in Patients with Allergy to Polyethylene Glycol. <i>Journal of the American Society of Echocardiography</i> , 2021, 34, 707-708.	2.8	25
5	Graft-versus-host disease after liver transplantation is associated with bone marrow failure, hemophagocytosis, and DNMT3A mutations. <i>American Journal of Transplantation</i> , 2021, 21, 3894-3906.	4.7	11
6	New onset diabetes after kidney transplantation in Asian Americans – Is there an increased risk?. <i>Transplantation Reports</i> , 2021, 6, 100080.	0.4	1
7	Cytomegalovirus serologic matching in deceased donor kidney allocation optimizes high- and low-risk (D+R ⁺ and D ⁻ R ⁺) profiles and does not adversely affect transplant rates. <i>American Journal of Transplantation</i> , 2020, 20, 3502-3508.	4.7	12
8	De novo thrombotic microangiopathy in two kidney transplant recipients from the same deceased donor: A case series. <i>Clinical Transplantation</i> , 2020, 34, e13885.	1.6	6
9	Lipid-lowering agents for the treatment of hyperlipidemia in patients with chronic kidney disease and end-stage renal disease on dialysis: a review. <i>Drugs and Therapy Perspectives</i> , 2019, 35, 431-441.	0.6	3
10	Sulfonamide desensitization in solid organ transplant recipients: A protocol-driven approach during the index transplant hospitalization. <i>Transplant Infectious Disease</i> , 2019, 21, e13191.	1.7	7
11	Biologic targeted therapy in allergic asthma. <i>Journal of Precision Respiratory Medicine</i> , 2019, 2, 24-34.	0.1	0
12	The efficacy and safety of direct oral anticoagulants in patients with chronic renal insufficiency: A review of the literature. <i>European Journal of Haematology</i> , 2019, 102, 312-318.	2.2	53
13	Outcomes of Kidney Transplantation with a CMV Matching Allocation Schema. <i>Open Forum Infectious Diseases</i> , 2017, 4, S11-S12.	0.9	1
14	Adherence Rates Between Once and Twice Daily Direct Oral Anticoagulants - Results of a Single University Pharmacy Cohort Study. <i>Blood</i> , 2016, 128, 5024-5024.	1.4	0
15	Drug Dosing in Patients with Chronic Kidney Disease and Dermatological Diseases. , 2015, , 221-253.		0
16	Tacrolimus exposure in the real world: an analysis from the <sc>M</sc>ycophenolic acid <sc>O</sc>bservational <sc>RE</sc>nal transplant study. <i>Clinical Transplantation</i> , 2014, 28, 768-775.	1.6	7
17	Pharmacokinetics of Lipid-Lowering Medications in Chronic Kidney Disease. , 2014, , 129-152.		0
18	Drug Dosing in Elderly Patients with Chronic Kidney Disease. <i>Clinics in Geriatric Medicine</i> , 2013, 29, 657-705.	2.6	17

#	ARTICLE	IF	CITATIONS
19	HMG-CoA Reductase Inhibitors in Chronic Kidney Disease. American Journal of Cardiovascular Drugs, 2013, 13, 385-398.	2.2	4
20	The Old and New Methods of Assessing Kidney Function. Journal of Clinical Pharmacology, 2012, 52, 63S-71S.	2.0	16
21	Drug dosing in patients with chronic kidney disease. , 2012, , 197-206.		0
22	Evaluation of Potential Interactions between Mycophenolic Acid Derivatives and Proton Pump Inhibitors. Annals of Pharmacotherapy, 2012, 46, 1054-1064.	1.9	17
23	Three strikes and statins out: A case against use of statins in dialysis patients for primary prevention. Dialysis and Transplantation, 2011, 40, 148-151.	0.2	0
24	A Quantitative Approach to Drug Dosing in Chronic Kidney Disease. Blood Purification, 2011, 31, 138-145.	1.8	35
25	The Efficacy and Safety of the 3-Hydroxy-3-methylglutaryl-CoA Reductase Inhibitors in Chronic Kidney Disease, Dialysis, and Transplant Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 664-678.	4.5	25
26	Topics in Transplantation Medicine for General Nephrologists. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1518-1529.	4.5	0
27	Epidemiology and Outcomes of Candidemia in 2019 Patients: Data from the Prospective Antifungal Therapy Alliance Registry. Clinical Infectious Diseases, 2009, 48, 1695-1703.	5.8	809
28	Drug Dosing in the Elderly Patients with Chronic Kidney Disease. Clinics in Geriatric Medicine, 2009, 25, 459-527.	2.6	43
29	Presentation of the PATH Alliance® registry for prospective data collection and analysis of the epidemiology, therapy, and outcomes of invasive fungal infections. Diagnostic Microbiology and Infectious Disease, 2007, 59, 407-414.	1.8	81
30	Primer on Kidney Diseases. Annals of Internal Medicine, 2006, 144, 784.	3.9	0
31	Autosomal-dominant polycystic kidney disease as a risk factor for diabetes mellitus following renal transplantation. Kidney International, 2005, 67, 714-720.	5.2	75
32	Cardiovascular complications of immunosuppressive agents in renal transplant recipients. Expert Opinion on Drug Safety, 2005, 4, 29-44.	2.4	8
33	Hepatitis C infection increases the risk of new-onset diabetes after transplantation in liver allograft recipients. American Journal of Surgery, 2005, 189, 552-557.	1.8	40
34	Comparative Analysis of Outcome Following Liver Transplantation in US Veterans. American Journal of Transplantation, 2004, 4, 788-795.	4.7	19
35	Management of invasive aspergillosis in high-risk patients. Managed Care Interface, 2004, Suppl B, 7-21; quiz 22-3.	0.2	0
36	Graft Failure From Severe Recurrent Primary Sclerosing Cholangitis Following Orthotopic Liver Transplantation. Journal of Clinical Gastroenterology, 2003, 37, 344-347.	2.2	14

#	ARTICLE	IF	CITATIONS
37	Multicenter Evaluation of Risk Factors for Aspergillosis in Patients Treated with Lipid Amphotericin B Products: Outcomes, Drug Utilization Parameters, and Benchmarking. <i>Hospital Pharmacy</i> , 2003, 38, 232-240.	1.0	1
38	Immunosuppression impact on long-term cardiovascular complications after liver transplantation. <i>American Journal of Surgery</i> , 2002, 183, 595-599.	1.8	110
39	Late mortality after orthotopic liver transplantation. <i>American Journal of Surgery</i> , 2001, 181, 475-479.	1.8	108
40	Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies. <i>Current Opinion in Critical Care</i> , 2001, 7, 384-389.	3.2	257
41	Use of basiliximab and daclizumab in kidney transplantation. <i>Progress in Transplantation</i> , 2001, 11, 33-39.	0.7	13
42	RITUXIMAB IS SAFE AND EFFECTIVE FOR THE TREATMENT OF POST TRANSPLANT LYMPHOPROLIFERATIVE DISEASE.. <i>Transplantation</i> , 2000, 69, S321.	1.0	0
43	Renal toxicity of protease inhibitors. <i>Current Opinion in Nephrology and Hypertension</i> , 2000, 9, 473-476.	2.0	31
44	Effect of grapefruit juice on cyclosporin A pharmacokinetics in pediatric renal transplant patients. <i>Pediatric Transplantation</i> , 2000, 4, 313-321.	1.0	28
45	Association of fungal infection and increased mortality in liver transplant recipients. <i>American Journal of Surgery</i> , 2000, 179, 426-430.	1.8	85
46	Nephrotoxicity of immunosuppressive drugs: Long-term consequences and challenges for the future. <i>American Journal of Kidney Diseases</i> , 2000, 35, 333-346.	1.9	378
47	Fatal Fulminant Hepatitis Associated with Bromfenac Use. <i>Annals of Pharmacotherapy</i> , 1999, 33, 945-947.	1.9	39
48	Immunosuppressant-Induced Nephropathy. <i>Drug Safety</i> , 1999, 21, 471-488.	3.2	96
49	A Practical Guide to the Management of Hypertension in Renal Transplant Recipients. <i>Drugs</i> , 1999, 58, 1011-1027.	10.9	57
50	Distant processing of pancreas islets for autotransplantation following total pancreatectomy. <i>American Journal of Surgery</i> , 1999, 177, 423-427.	1.8	65
51	Vancomycin-resistant Enterococcus in liver transplant patients. <i>American Journal of Surgery</i> , 1999, 177, 418-422.	1.8	64
52	Hepatic allograft abscess with hepatic arterial thrombosis. <i>American Journal of Surgery</i> , 1998, 175, 354-359.	1.8	47
53	LIVER TRANSPLANTATION FOR DISULFIRAM-INDUCED HEPATIC FAILURE. <i>American Journal of Gastroenterology</i> , 1998, 93, 830-831.	0.4	21
54	EFFICACY AND SAFETY OF LOW MOLECULAR WEIGHT HEPARIN IN RENAL TRANSPLANTATION1. <i>Transplantation</i> , 1998, 66, 533-534.	1.0	41

#	ARTICLE	IF	CITATIONS
55	Switching Between Cyclosporin Formulations What are the Risks?. Drug Safety, 1997, 16, 366-373.	3.2	27
56	DEVELOPMENT OF GANCICLOVIR RESISTANCE DURING TREATMENT OF PRIMARY CYTOMEGALOVIRUS INFECTION AFTER LIVER TRANSPLANTATION1. Transplantation, 1997, 63, 476-478.	1.0	65
57	Pharmacology of immunosuppressive medications used in renal diseases and transplantation. American Journal of Kidney Diseases, 1996, 28, 631-667.	1.9	63